<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00805064</url>
  </required_header>
  <id_info>
    <org_study_id>MK-KTRVO-2008</org_study_id>
    <nct_id>NCT00805064</nct_id>
  </id_info>
  <brief_title>Combined Triple Procedure in Retinal Vein Occlusion (RVO)</brief_title>
  <official_title>Intravitreal Combination Therapy Using Triamcinolone and Bevacizumab Improves Vision in Patients With Retinal Vein Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot study was to investigate the effects of an intravitreal combination
      therapy using triamcinolone and bevacizumab in patients with retinal vein occlusion (RVO).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective study of a case series was conducted in 47 patients (n = 47 eyes; f/m:
      21/26; mean age: 66.6 years) with ischemic central RVO (CRVO) (n = 15), non-ischemic CRVO (n
      = 7), or branch RVO (BRVO) (n = 25). A core pars plana vitrectomy with aspiration of 1.5 ml
      vitreous and infusion of balanced salt solution (BSS; 1 ml), 8 mg (0.4 ml) triamcinolone, and
      1.25 mg (0.1 ml) bevacizumab was performed with a single sutureless sclerotomy and a 23 gauge
      probe tip. At baseline and follow-up, the best corrected visual acuity (BCVA; 6 m Snellen),
      and intraocular pressure (IOP; Goldmann tonometry), and central macular thickness (optical
      coherence tomography) were determined. In addition, the need for further treatment and
      adverse events were monitored.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BCVA</measure>
    <time_frame>day of exam</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>ischemic CRVO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment was applied to this entity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non ischemic CRVO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment was applied to this entity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BRVO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment was applied to this entity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triamcinolone and bevacizumab</intervention_name>
    <arm_group_label>ischemic CRVO</arm_group_label>
    <arm_group_label>non ischemic CRVO</arm_group_label>
    <arm_group_label>BRVO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ischemic central RVO (CRVO)

          -  Non-ischemic CRVO

          -  Branch RVO (BRVO)

        Exclusion Criteria:

          -  Visual deterioration due to acute or chronic inflammation

          -  Post trauma

          -  Macular edema of other origin

          -  Intravitreal drug treatment within last 4 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Koss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of VitreoRetinal Surgery ZAU JWGU</affiliation>
  </overall_official>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2008</study_first_posted>
  <last_update_submitted>September 26, 2012</last_update_submitted>
  <last_update_submitted_qc>September 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Michael Koss</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

